Preliminary results showed that the 99mTc-HYNIC-ADH-1 molecular probe could be used for imaging of drug-resistant NSCLC, providing a noninvasive method to dynamically observe whether NSCLC patients develop drug resistance during treatment. The gene discussed is ADH1A; the disease is non-small cell lung carcinoma.